Physician profile
Michael C Schweitz
NPI 1700886371
$42,837.61
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $21K · 2021: $12K · 2022: $133 · 2023: $18.17 · 2024: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Rheumatology | $33,750.00 | 2019-2021 | |
| Janssen Biotech, INC. | $2,055.23 | 2019-2024 | Tremfya |
| Amgen INC. | $1,580.20 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $1,077.44 | 2019-2021 | |
| Pfizer INC. | $841.11 | 2019-2021 | |
| Ucb, INC. | $807.49 | 2019-2021 | |
| Abbvie INC. | $652.84 | 2019-2022 | |
| Johnson & Johnson Health Care Systems INC. | $458.29 | 2019-2022 | |
| Glaxosmithkline, LLC. | $438.93 | 2019-2021 | |
| Lilly USA, LLC | $251.92 | 2019-2021 | |
| Radius Health, INC. | $183.98 | 2019-2021 | |
| Horizon Therapeutics Plc | $141.91 | 2019-2021 | |
| Sobi, INC | $141.87 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $119.08 | 2019-2020 | |
| Celgene Corporation | $99.73 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $70.11 | 2019-2020 | |
| Genentech USA, INC. | $53.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.84 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.63 | 2019 | |
| Orthogenrx INC. | $19.34 | 2019 | |
| Aurinia Pharma U.S., INC. | $18.17 | 2023 | Lupkynis |
| Bioventus LLC | $16.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schweitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.